

**Perfusion scintigraphy and patient selection for lung volume reduction surgery**

*Divay Chandra, MD MSc, David A Lipson, MD, Eric A Hoffman, PhD, John Hansen-Flaschen, MD*

*Frank C Sciurba, MD, Malcom M DeCamp, MD, John J Reilly, MD, and George R Washko, MD, for the NETT*

*Research Group*

**Online data supplement**

Major enrollment criteria were:

1. Bilateral emphysema with  $FEV_1 \leq 45\%$  predicted
2. Total lung capacity  $\geq 100\%$  predicted
3. Residual volume  $\geq 150\%$  predicted
4.  $PaCO_2 \leq 60$  mm Hg ( $PaCO_2 \leq 55$  mm Hg in Denver, CO).

## Supplementary figures

**Figure E1.** Kaplan-Meier survival curves after randomization for patients with non-upper lobe predominant emphysema ( $n = 357$ ). Among those with low exercise capacity (panel A1) mortality was similar with LVRS or optimal medical management (RR = 0.78,  $p = 0.18$ ). This did not change after classifying patients as having low or high upper-zone perfusion (panel A2, RR = 0.88,  $p = 0.38$ , and panel A3, RR = 0.76,  $p = 0.21$ , respectively). Among those with high exercise capacity (panel B1) survival was also similar with LVRS and optimal medical management (RR = 1.2,  $p = 0.20$ ). This did not change after classifying patients as having low or high upper-zone perfusion (panel B2, RR = 1.8,  $p = 0.33$ , and panel B3, RR = 1.1,  $p = 0.35$ , respectively).

**Figure E2.** A comparison of frequency of improvement in functional outcomes after randomization to lung volume reduction surgery (LVRS, black bars) vs. optimal medical treatment (OMT, grey bars) for patients with non-upper lobe predominant emphysema and low exercise capacity at baseline. Outcomes were mostly better with LVRS though these improvements did not persist till 3 years after randomization (column C1). This remained true after patients were classified as having low (column C2) or high upper-zone perfusion (column C3). The sample size was smaller in the low compared to the high perfusion group (39 vs. 100) which likely resulted in the non-significant  $p$ -values at 1 year follow-up in those with low perfusion.


**Figure E3.** A comparison of frequency of improvement in functional outcomes after randomization to lung volume reduction surgery (LVRS, black bars) vs. optimal medical treatment (OMT, grey bars) for patients with non-upper lobe predominant emphysema and high exercise capacity at baseline. Outcomes were mostly better with LVRS though improvements did not persist 3 years after randomization (column D1). This remained true after patients were classified as having low (column D2) or high upper-zone perfusion (column D3). The sample size was smaller in the low compared to the high perfusion group (34 vs. 96) which likely resulted in the non-significant  $p$ -values at 1 year follow-up in those with low perfusion.

**Figure E4.** A comparison of different cutoffs for defining low vs. high upper-zone perfusion. 20% appeared to be the best cut-off because the odds ratio started to approach one when the cutoff was increased or decreased

from 20%. The cutoff of 20% also resulted in the narrowest confidence interval for the odds ratio. Note: x-axis is not to scale.

**Figure E1.**


**A1. Non-upper lobe predominance, low exercise capacity (n = 145)**



No. at risk

Surgery	82	64	44	33	12	2
Medical therapy	63	44	32	19	7	1


**A2. Non-upper lobe predominance, low exercise capacity, and low upper zone perfusion (n = 36)**



No. at risk

Surgery	21	18	10	8	3	1
Medical therapy	15	12	10	5	2	1


**A3. Non-upper lobe predominance, low exercise capacity, and high upper zone perfusion (n = 109)**



No. at risk

Surgery	61	47	35	26	10	1
Medical therapy	48	33	23	15	6	1


**B1. Non-upper lobe predominance, high exercise capacity (n = 212)**



No. at risk

Surgery	107	90	75	59	23	2
Medical therapy	105	97	77	60	23	4


**B2. Non-upper lobe predominance, high exercise capacity, and low upper zone perfusion (n = 39)**



No. at risk

Surgery	19	16	13	11	5	1
Medical therapy	20	19	19	16	7	3


**B3. Non-upper lobe predominance, high exercise capacity, and high upper zone perfusion (n = 173)**



No. at risk


Surgery	88	75	63	49	19	2
Medical therapy	85	77	59	45	17	2

**Figure E2.**



\*  $\geq 10$  Watt improvement in exercise capacity; †  $\geq 100$  mL improvement in FEV<sub>1</sub>; ‡  $\geq 8$  point improvement in total SGRQ score; §  $\geq 5$  point improvement in SOBQ score from baseline.


1 **Figure E3.**



2

\*  $\geq 10$  Watt improvement in exercise capacity; †  $\geq 100$  mL improvement in FEV<sub>1</sub>; ‡  $\geq 8$  point improvement in total SGRQ score; §  $\geq 5$  point improvement in SOBQ score from baseline.

1 **Figure E4.**



2

3

4